Dual Inhibition of CDK12 and CDK13 Uncovers Actionable Vulnerabilities in Patient-Derived Ovarian Cancer Organoids

Viability assays with high grade serous ovarian cancer cells and patient-derived organoids were performed to assess the efficacy of the CDK12/13 inhibitor, THZ531, as single agent or in combination with clinically relevant drugs.